icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
2019 April 10-14
Vienna Austria
Back grey_arrow_rt.gif
Achieving accelerated elimination of hepatitis C
virus infection by 2025: a case study in France

  Reported by Jules Levin
EASL 2019 April 10-14 Vienna
Victor de Ledinghen1, Christophe Bureau2, Yuri Sanchez Gonzalez3, Fabrice Ruggeri4, Homie Razavi5
1 CHU de Bordeaux, Bordeaux, France, 2 CHU de Toulouse, Toulouse, France, 3 AbbVie Inc., North Chicago, USA, 4 AbbVie France Ltd., Rungis, France, 5 Center for Disease Analysis, Lafayette, USA
"France is on track to achieve the World Health Organization's (WHO) targets for elimination of HCV as a public health threat by 2030" "By 2030, accelerated elimination would yield cost savings of (Pound)162 million, with an ICER of Pound-9,635/QALY"
"By 2030, accelerated elimination would avert:
-7,244 new HCV infections,
-74 cases of decompensated cirrhosis
-144 cases of hepatocellular carcinoma
-16 liver transplantations
-107 liver-related deaths"